TORNA ALL’ELENCO

MUSCULOSKELETAL ULTRASOUND BASELINE ASSESSMENT IMPROVES THE RESPONSE TO APREMILAST IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM A MULTICENTER STUDY in Annals of the Rheumatic Diseases

2023
ASL Novara

Tipo pubblicazione

Conference Abstract

Autori/Collaboratori (37)Vedi tutti...

Farina A
Internal Medicine Unit, Rheumatology Outpatient Clinic, Fermo, Italy
Del Medico P
Rheumatology Outpatient Clinic, Internal Medicine Unit, Civitanova Marche, Italy
Becciolini A
Department of Medicine, Internal Medicine and Rheumatology Unit, Parma, Italy

et alii...

Abstract

Background: Psoriatic arthritis (PsA) is an inflammatory rheumatic disease characterized by different phenotypes in terms of joint involvement. Apremilast, PDE4 competitive inhibitor, has been introduced in the treatment of adult psoriatic arthritis (PsA) with moderate disease activity. Musculoskeletal ultrasound (MUS) is useful in the assessment of disease, treatment response and follow up in PsA patients. Choosing an effective and safe treatment over time is an increasingly urgent goal given the greater availability of indicated drugs. Objectives: The aim of this study is to evaluate if MUS assessment before apremilast treatment can improvement its retention rate. Methods: We enrolled consecutive patients affected by PsA (according to the CASPAR Criteria) from 15 rheumatology centers. The following data were recorded for each patient: age, gender, duration of disease, DAPSA; smoke, comorbilities; concomitant treatment; duration of therapy with apremilast; reason of sospensione, PsA phenotype (poliarticular or oligoarticular) (Table 1). All patients were divided in two subset according to the presence of a MUS assessment before apremilast treatment. The differentes between two groups were calculated by means of the Mann-Whitney and Chi-quadro tests. The Kaplan Meier curve and Cox analysis assessed the retention rate and associated factors. P values < 0.05 were considered statistically significant. Results: ON Three hundred and fifty patients (m/f: 198/152; median age 60 years, IQR 52-67 years), 40% received MUS examination. In the MUS group there was a moderate disease (medium 22,9 IQR 18,2-29 vs 26,9 IQR 20,3-33,9; p=0,0006) and a prevalence of the oligoarticular pattern (73% vs 44%, p<0,0001). The retention rate was statistically higher in MUS group (Figure 1) (HR 0,57 IC95% 0,35-0,95; p=0,03). Conclusion: In PSA patients treated with apremilast, MUS assessment at baseline was associated with an higher retetion rate. MUS could be useful in the PsA treatmen

DOI : 10.1136/annrheumdis-2023-eular.5485

Keywords

apremilast; adult; algorithm; clinical assessment; conference abstract; controlled study; disease assessment; drug therapy; female; gender; human; IC95; Kaplan Meier method; major clinical study; male; middle aged; multicenter study; phenotype; prevalence; psoriatic arthritis; rheumatology; smoke; treatment duration; ultrasound;